Physician profile
Ruby S John
NPI 1629224118
$1,616.79
in general payments reported to CMS, 2019-2025
24 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.20 · 2022: $419 · 2023: $394 · 2024: $583 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $256.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $197.60 | 2022-2024 | Breztri, Airsupra |
| Abbott Laboratories | $162.27 | 2022-2024 | Freestyle Libre 3, Confirm Rx |
| Baxter Healthcare | $136.40 | 2022 | |
| Lilly USA, LLC | $113.28 | 2022-2024 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $112.01 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $95.10 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.86 | 2022-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $66.18 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $57.60 | 2023-2025 | Venaseal, Inceptiv |
| Pfizer INC. | $49.35 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.53 | 2024-2025 | Jardiance |
| Phadia US INC. | $35.04 | 2023-2024 | Immunocap |
| Horizon Therapeutics Plc | $26.58 | 2022 | |
| Vifor Pharma, INC. | $25.59 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $23.15 | 2025 | |
| Si-Bone, INC. | $23.02 | 2022 | |
| Itamar Medical INC | $19.15 | 2024 | Watchpatone |
| Becton, Dickinson and Company | $18.96 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
| Echosens North America, INC. | $17.36 | 2024 | Fibroscan |
| Exact Sciences Corporation | $16.08 | 2024 | Cologuard Collection Kit |
| Vbi Vaccine (Delaware) INC. | $15.61 | 2023 | Prehevbrio |
| Abbvie INC. | $14.07 | 2022 | |
| Dynavax Technologies Corporation | $10.24 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.